RE:Big Pharma making multi-billion $$ biotech acquisitions The recent M&A developments in the pharma and biotech sector are triggering revived interest in late-stage biotech companies like ONCY, which is proving pelareorep is prepared for 2 Phase 3 ready registration studies and the newly IRA announced FDA opportunity for an accelerated approval.